Samsara BioCapital

Founded 2016

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 59
Average round size
info
The average size of a deal this fund participated in
$87M
Portfolio companies 56
Rounds per year 11.80
Lead investments 6
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Exits 21
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

The main department of described Corporate Investor is located in the Palo Alto. The company was established in North America in United States.

The real fund results show that this Corporate Investor is 0 percentage points less often commits exit comparing to other companies. Opposing the other organizations, this Samsara BioCapital works on 1 percentage points more the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 50 - 100 millions dollars. The important activity for fund was in 2019. The increased amount of exits for fund were in 2019.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Samsara BioCapital, startups are often financed by Alta Partners, Skyline Ventures, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are Redmile Group, EcoR1 Capital, Cormorant Asset Management. In the next rounds fund is usually obtained by UBS Oncology Impact Fund, Redmile Group, EcoR1 Capital.

The overall number of key employees were 2.

We can highlight the next thriving fund investment areas, such as Clinical Trials, Health Care. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline ElevateBio, ElevateBio, AlloVir For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Samsara BioCapital:
Typical Co-investors
Samsara BioCapital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Samsara BioCapital:

Funds with similar focus

Funds from United States, Palo Alto
Funds with similar focus located in United States, Palo Alto:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Sands Brothers Asset Management United States, New York
Nirvana Capital China, Beijing
Otter Media United States, Santa Monica
Frontline Ventures United Kingdom, London
MOGU China, Hangzhou
Tennant Capital Partners United States, Saint Louis
Hamilton Ventures LLC United States, Atlanta
Drake Management United States, Nyack
SXSW Interactive United States, Austin
Kloeckner & Co Germany, Duisburg
Hargreave Hale United Kingdom, London
Colour Life Services Group China, Shenzhen
Grupo Picking Pack -
Hallador Investment Advisors -
Huaxin Zhongcheng Investment China, Guangdong
First Check Ventures -
Chelsea Vanguard Fund -
UNT Group -
Shenzhen Huijing Tongda Business Consulting China, Shenzhen
Arno Capital Israel, Ramat Gan

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Neurogastrx

Biotechnology
Health Care
Health Diagnostics
Pharmaceutical
1
$60M26 Aug 2021 United States, " United States"}

Pepgen

Biotechnology
Clinical Trials
Medical
n/a
$112M05 Aug 2021 United Kingdom, Oxford

Prime Medicine

Biotechnology
Medical
1
$200M13 Jul 2021 United States, Cambridge

Abata Therapeutics

Biotechnology
Medical
Therapeutics
1
$95M23 Jun 2021 United States, Cambridge

Synthekine

Biotechnology
Therapeutics
1
$107M10 Jun 2021 United States, " United States"}

NiKang Therapeutics

Biotechnology
Health Care
Medical
1
$200M26 May 2021 United States, Wilmington

Vedere Bio

Biotechnology
Health Care
Therapeutics
1
$77M18 May 2021 United States, Cambridge

Arcellx

Biopharma
Health Care
Pharmaceutical
1
$115M13 Apr 2021 United States, " United States"}

ElevateBio

Biotechnology
Genetics
Health Care
Therapeutics
1
$525M15 Mar 2021 United States, Cambridge
News
Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Samsara BioCapital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: